research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
Search
for
Sort by
Research
330-360 / 1000+ results research Joint study of the associations of HLA‐B and the transmembrane short tandem repeat polymorphism of MICA protein with alopecia areata shows independent associations of both with the disease
Both HLA-B and MICA are independently linked to alopecia areata.
research Alopecia Universalis: an extremely rare but probable adverse effect of adalimumab
Adalimumab can cause complete hair loss in rare cases.
research Bidirectional association between alopecia areata and migraine: A nationwide population-based cohort study
People with alopecia areata are more likely to get migraines, and vice versa.
research Alopecia Areata
Alopecia Areata is an autoimmune disease causing hair loss in patches, often starting before age 20, and while some cases recover on their own, treatments include topical corticosteroids, minoxidil, and promising new methods like IL-31 antibodies and 308-nm Excimer laser therapy.
research 537 Periodontitis may increase risk of alopecia areata: A nationwide population-based cohort study in Korea
Periodontitis may increase the risk of developing alopecia areata.
research Alopecia Areata in Underrepresented Groups: Preliminary Analysis of the All of Us Research Program
Blacks and Hispanics have higher chances of alopecia areata than Whites.
research Alopecia Induced by Poly-L-Lactic Acid Injection
Poly-L-lactic acid injections can cause hair loss and skin issues.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Alopecia Areata Incognita: A Case Report
Alopecia Areata Incognita causes sudden hair loss in young females but usually has a better outcome than other types.
research Comparison of Alopecia areata in Human and Nonhuman Mammalian Species
The document concludes that certain rats and mice are useful for studying hair loss in humans and testing treatments.
research Comparative Efficacy of Oral and Topical 5-Alpha Reductase Inhibitors in Reducing Dihydrotestosterone levels across Men with Androgenetic Alopecia: A Network Meta-Analysis incorporating Post-Hoc Analyses of Randomized Clinical Trial Data
Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
research Both Retinoic Acid Receptors α (RARα) and γ (RARγ) Are Able to Initiate Mouse Upper-Lip Skin Glandular Metaplasia
research Novel Missense Mutation in the P-Box of Androgen Receptor in a Patient with Androgen Insensitivity Syndrome
A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.
research Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research The Pathogenesis of Alopecia Areata in Rodent Models
Alopecia Areata is an autoimmune disease affecting hair follicles, influenced by genetic and environmental factors, with rodent models being essential for research.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Excimer lamp as an effective alternative treatment for severe alopecia areata
The excimer lamp is a safe and effective treatment for severe alopecia areata.
research Alopecia Areata
The document concludes that ongoing research using animal models is crucial for better understanding and treating Alopecia Areata.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
research Role of ASLNC168501 in regulating hair follicle stem cell activity via the AR/miR-128-3p/IGF-1 pathway
ASLNC168501 can help treat hair loss by restoring hair follicle stem cell function.
research 44179 Characterization of subclinical atherosclerosis in chronic severe alopecia areata.
Severe alopecia areata may increase the risk of hidden artery disease.
research Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia
New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
research Evaluation of Anthralin in the Treatment of Alopecia Areata
Anthralin cream helped 25% of patients with severe alopecia areata regrow hair, but caused skin irritation.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.